Electrolyte Complex

Both support muscle function and hydration

Optimal muscle performance and hydration

✦ Magnesium

enhances

Key electrolyte often deficient

Complete electrolyte support

⟡ Glycerol

Sodium helps retain the extra fluid

Enhanced hyperhydration and electrolyte balance

⟡ Potassium

Sodium and potassium work in opposition

Optimal blood pressure regulation

Top studies from 40+ peer-reviewed papers

📚meta-analysisn=1140

Liang Y et al. • The Cochrane database of systematic reviews (2019)

“Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age.”

Key Findings:

Racecadotril may reduce the risk of rehydration failure (RR 0.41, 95% CI 0.13 to 1.23; 2 RCTs, 192 participants; low-certainty evidence).
Length of hospital stay was similar in two studies measuring this, and overall there was no evidence that racecadotril increased overall rate of adverse events (RR 0.90, 95% CI 0.66 to 1.22; 5 RCTs, 688 participants; low-certainty evidence).
Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age.

📚meta-analysisn=4284

Gregorio GV et al. • The Cochrane database of systematic reviews (2016)

“Polymer-based ORS shows advantages compared to glucose-based ORS (at ≥ 310 mOsm/L).”

Key Findings:

Polymer-based ORS may decrease mean stool output in the first 24 hours by 24 mL/kg (mean difference (MD) -24.60 mL/kg, 95% CI -40.69 to -8.51; one trial, 99 participants, low quality evidence).
The average duration of diarrhoea may be reduced by eight hours (MD -8.24 hours, 95% CI -13.17 to -3.30; I² statistic = 86%, five trials, 364 participants, low quality evidence) with polymer ORS but results are heterogeneous.
Limited trials showed no observed difference in the risk of unscheduled use of intravenous fluid (RR 0.66, 95% CI 0.43 to 1.02; I² statistic = 30%; four trials, 376 participants, very low quality evidence), vomiting (very low quality evidence), and hyponatraemia (very low quality evidence).
The proportion of participants that required intravenous hydration was low in most trials with fewer in the polymer ORS group (RR 0.75, 95% CI 0.57 to 0.98; 19 trials, 1877 participant, low quality evidence) .

📚meta-analysisn=4623

Leibovici-Weissman Y et al. • The Cochrane database of systematic reviews (2014)

“In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects observed in severely and non-severely ill patients.”

Key Findings:

Antimicrobials versus placebo or no treatment Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence).
In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects observed in severely and non-severely ill patients.
Azithromycin and tetracycline may have some advantages over other antibiotics.

📚meta-analysisn=718

Musekiwa A et al. • The Cochrane database of systematic reviews (2011)

“In people with cholera, ORS ≤ 270 is associated with biochemical hyponatraemia when compared with ORS ≥ 310, but there are no differences in terms of other outcomes.”

Key Findings:

We found no statistically significant difference in the need for unscheduled intravenous infusion.
In people with cholera, ORS ≤ 270 is associated with biochemical hyponatraemia when compared with ORS ≥ 310, but there are no differences in terms of other outcomes.
Although this risk does not appear to be associated with any serious consequences, the total patient experience in existing trials is small.
Under wider practice conditions, especially where patient monitoring is difficult, caution is warranted.

📚meta-analysisn=1811

Compare with Others Find Based on Your Goals

Hartling L et al. • The Cochrane database of systematic reviews (2006)

“Although no clinically important differences between ORT and IVT, the ORT group did have a higher risk of paralytic ileus, and the IVT group was exposed to risks of intravenous therapy.”

Key Findings:

There were more treatment failures with ORT (RD 4%, 95% confidence interval (CI) 1 to 7, random-effects model; 1811 participants, 18 trials; NNT = 25).
Shorter hospital stays were reported for the ORT group (WMD -1.20 days, 95% CI -2.38 to -0.02 days; 526 participants, 6 trials).
Although no clinically important differences between ORT and IVT, the ORT group did have a higher risk of paralytic ileus, and the IVT group was exposed to risks of intravenous therapy.
For every 25 children (95% CI 14 to 100) treated with ORT one would fail and require IVT.

View all 40+ studies

What would you like to do next?

Related Supplements

Fe9.0

Iron

Essential mineral for oxygen transport and energy production — critical for those with deficiency, especially women and athletes.

Zn9.0

Zinc

Involved in 300+ enzymatic reactions — supports immune defense, testosterone production, wound healing, and sleep quality.

Mg8.5

Magnesium

8.5/10

Supports 300+ enzymatic reactions — critical for sleep, stress response, muscle function, and cognitive health.

Brt7.5

Beetroot

7.5/10

Dietary nitrates convert to nitric oxide, enhancing oxygen delivery to muscles — a top-5 evidence-based ergogenic aid.

Elc9.0

Electrolyte Complex

mineral

Electrolyte Supplement (Sodium, Potassium, Magnesium)

Essential minerals for hydration, muscle function, and performance — crucial for athletes, fasters, and those on low-carb diets.

recoveryenergyhydrationperformancemuscleketo

40+ studies

Evidence

Reviewed 19 days ago

moderate

Safety

Sodium 1000-3000mg, Potassium 1000-3500mg, Magnesium 200-400mg daily (varies by needs)

Dose

0-0 days

Time to Effect

Powder or capsules with balanced electrolyte blend

Best Form

Mechanisms of Action

💧

Fluid Balance

Regulates water distribution in body

⚡

Muscle & Nerve Function

Enables electrical signals

⚖️

pH Balance

Maintains proper body pH

Biological PathwayBeta

How Electrolyte Complex works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.

Supplement

Molecular Target

Biological Process

Health Outcome

Strong

Moderate

Emerging

strong

moderate

emerging

Tap node to isolate • Pinch to zoom • Tap edge for research

Recommended Dose

Sodium 1000-3000mg, Potassium 1000-3500mg, Magnesium 200-400mg daily (varies by needs)

1servings3servings

Loading: During intense exercise: 500-1000mg sodium per hour of activity

Optimal Timing

Before/during/after exercise
Throughout the day on keto/fasting

Can be taken without food

Available Forms

Form	Type
💊Powder or capsules with balanced electrolyte blend	Recommended
💊Salt tablets	Alternative
💊Coconut water	Alternative
💊Bone broth	Alternative

Look for products with meaningful amounts of sodium, potassium, and magnesium. Many commercial drinks are too low in sodium.

Duration

Minimum: 0 days

Optimal: 0 days

Cycling: Not required

Note: During exercise, consume regularly. For daily use, spread throughout the day. Potassium best taken with food.

💧

Improved Hydration

Better water retention and distribution

⚡ Immediate

90% of users notice thispositive

💪

Cramp Prevention

Reduced muscle cramps

⚡ Immediate

75% of users notice thispositive

⚡

Sustained Energy

Maintained energy during activity

⚡ Immediate

70% of users notice thispositive

🧘

Keto/Fasting Support

Prevents symptoms from low electrolytes

⚡ Immediate

80% of users notice thispositive

ModerateMax safe dose: Varies by individual needs and medical conditions

🟡

Kidney disease

Requires medical supervision — potassium can be dangerous

🟡

Heart conditions

Consult doctor — sodium and potassium affect heart rhythm

🟢

Pregnant/nursing

Generally safe; maintain normal electrolyte intake

Who Should NOT Take This

Kidney disease (potassium can accumulate)
Heart conditions (consult doctor for sodium/potassium)
Addison's disease

Drug Interactions

ACE inhibitors, ARBsmoderate

Can increase potassium levels — monitor

Diureticsmoderate

Can affect electrolyte balance — may need more or less

Heart medicationsmoderate

Electrolyte levels affect heart rhythm

Possible Side Effects

GI upset (from potassium/magnesium)

milduncommon

Tip: Take with food; spread doses

Bloating (from sodium)

milduncommon

Tip: Normal temporary water retention

Warnings

Those with kidney disease should NOT supplement potassium without supervision
Very high potassium can cause dangerous heart rhythms
Balance is key — excess sodium without potassium can cause issues

⟡ Creatine

Both support muscle function and hydration

Optimal muscle performance and hydration

✦ Magnesium

enhances

Key electrolyte often deficient

Complete electrolyte support

⟡ Glycerol

Sodium helps retain the extra fluid

Enhanced hyperhydration and electrolyte balance

⟡ Potassium

Sodium and potassium work in opposition

Optimal blood pressure regulation

Top studies from 40+ peer-reviewed papers

📚meta-analysisn=1140

Liang Y et al. • The Cochrane database of systematic reviews (2019)

“Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age.”

Key Findings:

Racecadotril may reduce the risk of rehydration failure (RR 0.41, 95% CI 0.13 to 1.23; 2 RCTs, 192 participants; low-certainty evidence).
Length of hospital stay was similar in two studies measuring this, and overall there was no evidence that racecadotril increased overall rate of adverse events (RR 0.90, 95% CI 0.66 to 1.22; 5 RCTs, 688 participants; low-certainty evidence).
Racecadotril seems to be a safe drug but has little benefit in improving acute diarrhoea in children under five years of age.

📚meta-analysisn=4284

Gregorio GV et al. • The Cochrane database of systematic reviews (2016)

“Polymer-based ORS shows advantages compared to glucose-based ORS (at ≥ 310 mOsm/L).”

Key Findings:

Polymer-based ORS may decrease mean stool output in the first 24 hours by 24 mL/kg (mean difference (MD) -24.60 mL/kg, 95% CI -40.69 to -8.51; one trial, 99 participants, low quality evidence).
The average duration of diarrhoea may be reduced by eight hours (MD -8.24 hours, 95% CI -13.17 to -3.30; I² statistic = 86%, five trials, 364 participants, low quality evidence) with polymer ORS but results are heterogeneous.
Limited trials showed no observed difference in the risk of unscheduled use of intravenous fluid (RR 0.66, 95% CI 0.43 to 1.02; I² statistic = 30%; four trials, 376 participants, very low quality evidence), vomiting (very low quality evidence), and hyponatraemia (very low quality evidence).
The proportion of participants that required intravenous hydration was low in most trials with fewer in the polymer ORS group (RR 0.75, 95% CI 0.57 to 0.98; 19 trials, 1877 participant, low quality evidence) .

📚meta-analysisn=4623

Leibovici-Weissman Y et al. • The Cochrane database of systematic reviews (2014)

“In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects observed in severely and non-severely ill patients.”

Key Findings:

Antimicrobials versus placebo or no treatment Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (MD -36.77 hours, 95% CI -43.51 to -30.03, 19 trials, 1013 participants, moderate quality evidence).
In treating cholera, antimicrobials result in substantial improvements in clinical and microbiological outcomes, with similar effects observed in severely and non-severely ill patients.
Azithromycin and tetracycline may have some advantages over other antibiotics.

📚meta-analysisn=718

Musekiwa A et al. • The Cochrane database of systematic reviews (2011)

“In people with cholera, ORS ≤ 270 is associated with biochemical hyponatraemia when compared with ORS ≥ 310, but there are no differences in terms of other outcomes.”

Key Findings:

We found no statistically significant difference in the need for unscheduled intravenous infusion.
In people with cholera, ORS ≤ 270 is associated with biochemical hyponatraemia when compared with ORS ≥ 310, but there are no differences in terms of other outcomes.
Although this risk does not appear to be associated with any serious consequences, the total patient experience in existing trials is small.
Under wider practice conditions, especially where patient monitoring is difficult, caution is warranted.

📚meta-analysisn=1811

Compare with Others Find Based on Your Goals

Hartling L et al. • The Cochrane database of systematic reviews (2006)

“Although no clinically important differences between ORT and IVT, the ORT group did have a higher risk of paralytic ileus, and the IVT group was exposed to risks of intravenous therapy.”

Key Findings:

There were more treatment failures with ORT (RD 4%, 95% confidence interval (CI) 1 to 7, random-effects model; 1811 participants, 18 trials; NNT = 25).
Shorter hospital stays were reported for the ORT group (WMD -1.20 days, 95% CI -2.38 to -0.02 days; 526 participants, 6 trials).
Although no clinically important differences between ORT and IVT, the ORT group did have a higher risk of paralytic ileus, and the IVT group was exposed to risks of intravenous therapy.
For every 25 children (95% CI 14 to 100) treated with ORT one would fail and require IVT.

View all 40+ studies

What would you like to do next?

Related Supplements

Fe9.0

Iron

Essential mineral for oxygen transport and energy production — critical for those with deficiency, especially women and athletes.

Zn9.0

Zinc